| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary biological target of didocosahexaenoin is not a specific protein or enzyme. It is a lipid molecule that can be incorporated into cell membranes and modulate their properties. Its effects are thought to be mediated through its role as a source of DHA, which can influence various signaling pathways. It has been suggested to affect the production of reactive oxygen species (ROS) and to modulate apoptotic pathways. However, the exact molecular targets and mechanisms of action are not well-defined. Its biological effects are likely due to the release of DHA upon hydrolysis, which can then be metabolized into bioactive lipid mediators.
|
|---|---|
| ln Vitro |
In PC3 cells, docosahexaenoic acid diglyceride (10–50 μM; 96 hours) causes apoptosis [1]. In human prostate cells, docosahexaenoic acid diglyceride (1 nM-100 μM; 96 hours) causes dose-dependent cytotoxicity [1]. The loss of mitochondrial membrane potential is significantly increased by docosahexaenoic acid diglyceride (30, 50 μM; 24 hours) [1].
In vitro studies have investigated the effects of didocosahexaenoin on cells. It has been shown to modulate the levels of reactive oxygen species (ROS) and to influence apoptosis. The specific effects depend on the cell type and the concentration used. As a DHA-containing lipid, it may also affect cell membrane fluidity and the function of membrane proteins. Its ability to act as a source of DHA suggests that it could have similar biological activities to free DHA, but the kinetics and efficiency of release may differ. Further in vitro studies are needed to fully characterize its biological activity. |
| ln Vivo |
Information regarding the in vivo activity of didocosahexaenoin in animal models is limited. Its biological activity has been primarily characterized through in vitro assays. As a source of DHA, it may have beneficial effects in vivo, but these have not been extensively studied. DHA itself is known to have anti-inflammatory and neuroprotective effects, but whether didocosahexaenoin can effectively deliver DHA in vivo and produce these effects is not clear. Further studies are required to determine its pharmacokinetic properties and its potential efficacy in animal models of disease.
|
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for didocosahexaenoin is not applicable. It is not a ligand that binds to a specific enzyme or receptor. Its biological effects are mediated through its incorporation into cell membranes and its role as a source of DHA. Its interaction with cells can be studied using lipid binding assays or by measuring its incorporation into cellular membranes using mass spectrometry. However, these are not "binding assays" in the traditional pharmacological sense. Its activity is more related to its metabolism and physical properties.
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: PC3 cells Tested Concentrations: 10, 20, 30, 40, 50 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Caused elevated levels of early apoptotic cells. Dramatically increased the level of activated caspase 3/7 for 6 h at 30 and 50 μM. Cell Cytotoxicity Assay[1] Cell Types: PC3, DU145, A2780 and A2780-CP70 carcinoma cells and MCF-7 and LNCaP cells Tested Concentrations: 1 nM-100 μM Incubation Duration: 96 hrs (hours) Experimental Results: Induced dose-dependent cytotoxicity with the strongest toxicity under 10.0 μM on DU145 and PC3 cells, A2780 and A2780-CP70 with IC50 of 3.20 and 3.82 μM, 4.6, 5.53 μM, respectively. The in vitro cellular assay for didocosahexaenoin involves treating cells with various concentrations of the compound. The effect on ROS production is measured using a fluorescent probe such as DCFH-DA. Apoptosis is evaluated using flow cytometry with Annexin V/PI staining or by measuring caspase-3/7 activity. The incorporation of DHA into cellular membranes can be assessed by lipid extraction and gas chromatography-mass spectrometry (GC-MS). Cell viability is assessed using standard assays like MTT. These assays are used to study the biological effects of this DHA diglyceride on cells. |
| Animal Protocol |
The in vivo animal experiment workflow for didocosahexaenoin has not been well-established. If an animal study were to be designed, it would likely involve the use of a mouse model. The compound would be administered via oral gavage or intraperitoneal injection, likely formulated in a lipid vehicle. The outcomes measured would depend on the specific research question, such as the effect on inflammation, oxidative stress, or cognitive function. The levels of DHA and its metabolites in tissues would be quantified by GC-MS to assess the bioavailability and metabolism of the compound. These studies would provide insights into its potential in vivo effects.
|
| References |
| Molecular Formula |
C25H40O5
|
|---|---|
| Molecular Weight |
420.58
|
| Exact Mass |
712.506
|
| CAS # |
124538-05-2
|
| PubChem CID |
53389484
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
748.5±60.0 °C at 760 mmHg
|
| Flash Point |
204.8±26.4 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
13.59
|
| tPSA |
72.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
52
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)CC(COC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)O
|
| InChi Key |
MXYFTPKXCFFQRG-GZSOIYOPSA-N
|
| InChi Code |
InChI=1S/C47H68O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-46(49)51-43-45(48)44-52-47(50)42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5-8,11-14,17-20,23-26,29-32,35-38,45,48H,3-4,9-10,15-16,21-22,27-28,33-34,39-44H2,1-2H3/b7-5-,8-6-,13-11-,14-12-,19-17-,20-18-,25-23-,26-24-,31-29-,32-30-,37-35-,38-36-
|
| Chemical Name |
[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-hydroxypropyl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3777 mL | 11.8883 mL | 23.7767 mL | |
| 5 mM | 0.4755 mL | 2.3777 mL | 4.7553 mL | |
| 10 mM | 0.2378 mL | 1.1888 mL | 2.3777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.